Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
By C. Courtney, D. Farrell, R. Gray, R. Hills, Lloyd Lynch, E. Sellwood, S. Edwards, W. Hardyman, J. Raftery, P. Crome and 3 more. The Lancet, 2004
888 citations recorded by the source corpus.
Subfields: Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/db593d398ef236524b528ae14dd689085c924f57
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. D. Ben
- G. Marucci
- R. Volpini
- Francesco Amenta
- M. Buccioni
- C. Lambertucci
Citations in the corpus
- Donepezil and memantine for moderate-to-severe Alzheimer's disease. (2012, neutral): “36 to <60 mo 19 (26) 20 (26) 21 (29) 31 (42) 91 (31)”
- Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. (2020, positive): “…benefits over some years (Joe and Ringman, 2019) The AD2000 trial, a randomized study including 565 patients with mildmoderate AD treated with donepezil for up to four years, has shown a cognitive benefit of about 0.8 points on the MMSE scale over the course of the study (Courtney et al., 2004).”